IO Biotech, Inc.

IOBT

US4497781090

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-15 pm EST			5-day change	1st Jan Change
0.7063 ^USD	-12.54%		-6.04%	-23.23%

Dec. 15	IO Biotech Announces Publication of Five-Year Clinical Outcomes of Phase 1/2 Trial in Nature Communications	CI
Nov. 21	IO Biotech, Inc. Announces Executive Changes	CI

IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma

Published on 01/09/2025 at 04:24 pm EST - Modified on 01/09/2025 at 04:25 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about IO Biotech, Inc.

Dec. 15	IO Biotech Announces Publication of Five-Year Clinical Outcomes of Phase 1/2 Trial in Nature Communications	CI
Nov. 21	IO Biotech, Inc. Announces Executive Changes	CI
Nov. 14	IO Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 14	IO Biotech reports $8.4 mln Q3 net loss	RE
Nov. 07	IO Biotech presents pre-clinical data highlighting the potential of additional therapeutic cancer vaccine candidates at the 2025 annual meeting of the Society for Immunotherapy of Cancer (SITC)	RE
Oct. 20	IO Biotech Presents Phase 3 Results for Cylembio Plus KEYTRUDA (Pembrolizumab) in First-Line Advanced Melanoma at ESMO 2025	CI
Sep. 30	IO Biotech Faces Setback as FDA Opposes Cylembio BLA Submission, Morgan Stanley Says	MT
Sep. 30	TD Cowen Downgrades IO Biotech to Hold From Buy	MT
Sep. 30	Morgan Stanley Downgrades IO Biotech to Equalweight From Overweight, Cuts Price Target to $0.39 From $4	MT
Sep. 29	IO Biotech Advised Against Filing Biologics License Application for Cylembio; Plans to Cut 50% of Workforce	MT
Sep. 29	Io Biotech Announces Restructuring Plan, Plans Global Workforce Reduction of ~50% with One-Time Charges of $1?1.5 Million	CI
Sep. 29	IO Biotech provides update following pre-BLA meeting with FDA	RE
Sep. 29	IO Biotech Provides Update Following Pre-BLA Meeting with FDA	CI
Sep. 09	IO Biotech, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 07:45 AM
Aug. 14	IO Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
Sep. 01	IO Biotech, Inc. - Special Call
Aug. 11	IO Biotech announces clinical improvement in progression free survival demonstrated in pivotal phase 3 trial of cylembio plus Keytruda (pembrolizumab) for the treatment of first-line advanced melanoma, but statistical significance narrowly missed	RE
Aug. 11	IO Biotech Says Phase 3 Advanced Melanoma Study Showed Improved Survival Rates	MT
Aug. 11	IO Biotech Shares Jump in Premarket on Positive Melanoma Treatment Trial Data	DJ
Aug. 11	IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal	RE
Aug. 11	IO Biotech's cancer vaccines shows improvement in late-stage study goal	RE
Aug. 11	IO Biotech Announces Topline Results of Pivotal Phase 3 Trial of Cylembio in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma	CI
Jul. 24	Io Biotech files prospectus relates to resale, from time to time for offering of up to 4.2 million shares by selling stockholders- SEC filing	RE
Jun. 04	IO Biotech Regains Compliance With Nasdaq Listing Rules	MT
May. 23	Io Biotech Inc Files For Resale Of Up To 5.6 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing	RE

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Companyâs product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotechâs lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Employees

Sector

Biotechnology & Medical Research

Calendar

May. 18 - Q1 2026 Earnings Release (Projected)

More about the company